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Summary A loading dose of MPA employing a regimen of 1,000mg six hourly for 8 doses can achieve
plateau levels above 100 ngml-1 within the first 36h of treatment, without any untoward toxicity. This raises
the possibility of shortening the time to response for this agent. The additional factor of the time required to
achieve adequate serum levels may explain the apparent contradictions between reports correlating response
rates and dose and those correlating serum level and response.
Medroxyprogesterone acetate (MPA) is one of the major
alternatives for second-line hormonal therapy in advanced
breast carcinoma. In a randomised trial of MPA versus
aminoglutethimide it was found that using MPA at a dose of
1,000mg p.o. daily, the mean time to response was 8.7
weeks, significantly quicker than aminoglutethimide (Canney
et al., 1987).
It has been suggested that the steady state serum level of
MPA required to obtain the maximum percentage of res-
ponses is lOOngml-1 or higher (Johnson et al., 1984; Schulz
et al., 1984). Previous pharmacokinetic studies have shown
that to obtain such steady state levels may require periods of
between one and 8 weeks' therapy (Schulz et al., 1984;
Blossey et al., 1984). In a randomised study it has been
shown that, when using intra-muscular MPA, a constant
dose of 300mg weekly was significantly inferior to that same
dose but preceded by one month's treatment with 1,000mg
weekly (Cavelli et al., 1984). This may have been due either
to a true dose response curve or to an unacceptably pro-
longed time taken for the low dose schedule patients to have
achieved adequate serum levels and so be able to respond to
the drug.
This study was designed to determine if therapeutic levels
of MPA could be reached earlier during the course of
treatment by using an oral loading dose of the drug, raising
the possibility that the time to obtain a response could be
shortened.
Patients and methods
All patients had histologically proven breast carcinoma and
were eligible for second-line hormonal therapy. All patients
had normal liver function at entry into the study. There were
no restrictions on prior treatment except that the patients
should not have received MPA previously. All patients were
admitted to hospital for the first four days after starting
loading dose MPA. Pulse and blood pressure were checked
at four-hourly intervals and subjective toxicity assessed daily.
Informed verbal consent was obtained prior to entry into the
study.
Two loading dose schedules of MPA (Farlutal, Farmitalia
Carlo-Erba) were tested:
Schedule A - 24h loading dose. MPA was given at a dose
of 1,000mg orally, six-hourly for 4 doses followed by 250mg
six-hourly maintenance. Seven patients were treated using
this regimen.
Schedule B - 48 h loading dose. MPA was given at a dose
of 1,000mg six-hourly for 8 doses followed by 250mg
twelve-hourly maintenance. Nine patients were treated using
this regimen.
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Venous blood was collected at times 0, 3, 6, 9, 12, 24, 36,
48, and 72h, after 7, 14, 21, and 28 days, and 8 weeks. For
those patients who received the 48h schedule extra samples
were taken between 40 and 60h following the start of
treatment.
Serum was stored at -20°C until analysis.
Assay methods
Serum levels of MPA were measured by radioimmunoassay
largely according to the method described by Shrimanker et
al. (1978), using antiserum (kindly donated by Dr K.
Fotherby) which was characterised in detail in that report. In
brief, 50p! serum was extracted vigorously with 3ml petro-
leum ether. After evaporation of the solvent under a stream
of air the extract was reconstituted in 2ml of 0.1M, pH 7.3
phosphate buffered saline containing 0.1% (w/v) gelatin, and
lOOjil aliquots were assayed in duplicate. [1,2-3H(N)]-MPA
(1.9TBqmmol-1) was purchased from New England
Nuclear. The intra- and inter-assay CVs were 4.7% and
9.8% respectively.
Results
Marked inter-patient variability was observed, with both
treatment schedules, particularly during the first 24h of
treatment. At 3 h following the first dose the serum concent-
ration of MPA varied between lOngml-1 and 785ngml-1.
Within both treatment groups two different groups of
patients could be identified retrospectively (Table I): those in
whom there was a low MPA level following the first dose
Table I MPA levels for each schedule. 'Plateau levels' are all
observations made between 1 and 4 weeks after the start of
treatment (see text for definition of groups)
Medroxyprogesterone
levels (ngml 1)
Observations Min. Max. Mean s.e.
Schedule A
6 hours Group I
Group 2
Plateau Group 1
Group 2
Schedule B
6 hours Group 1
Group 2
Plateau Group 1
Group 2
Not
grouped
6
8
6
12
2
4
8
10
10
69
67
110
23
75
100
84
43
352
146
254
40
785
199
700
22.0
138
101
181
31
363
148
244
(5.1)
(36)
(14)
(15)
(160)
(14)
(73)
5 85 137 110 (9)
Br. J. Cancer (1988), 58, 73-7674 P.A. CANNEY et al.
(<45ng ml-1 n=5, 'group 1') and those in whom there was
a high level following the first dose of MPA (>70ngml1,
n=8, 'group 2'). Three patients (all treated using schedule B)
did not have serum MPA levels estimated within the first 6h
(Figure 1).
Schedule A
Of the 7 patients studied 3 had a low serum MPA level
following the first dose. Of these one never attained a level
of 100ngml-1, but the other 2 patients achieved levels of
140ngml-1, but not until two weeks after the start of
treatment (Figure 2a). The remaining 4 patients all showed a
marked rise in serum MPA level after the first dose. All of
these reached levels of >100ngml-1 within 28h. However,
all also showed a transient dip in serum level after the first
24h of treatment before re-establishing steady plateau con-
centrations of MPA (Figure 2b).
Schedule B
All 9 patients achieved serum levels in excess of 100ngml-1
within the first 36h of starting treatment. Two patients had
low levels of MPA following he initial dose. One of the
patients, who did not have the serum MPA level estimated
within the first 6h had a low 18h level of 40ngml-1; this
and her subsequent pharmacokinetic course suggested that
she should also be included in this group. All three did
achieve serum concentrations in excess of 100ngml-1 but a
transient fall in serum level was seen during the first stages
of the maintenance therapy (Figure 3a). The remaining 6
patients all maintained serum concentrations of MPA
>100ngml-1 starting within the first 24h of treatment
(Figure 3b). Eight patients maintained serum concentrations
of MPA >100ngml-1 with the maintenance therapy of
500mg daily but one patient did demonstrate a fall to
46ngml-1 after 8 weeks treatment.
No patient developed symptoms attributable to side effects
of MPA during the first fortnight of the study. Thereafter 3
patients did experience MPA toxicity. Two patients were
known to be previously hypertensive and one was also
diabetic; no exacerbation of these prior illnesses occurred.
Discussion
The time to reach steady state serum levels of MPA is
determined by dose when different studies are compared.
For an oral dose of 1,500mg daily it may take from 4 to 20
days to reach plateau levels (Blossey et al., 1984), but
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Figure 2 Schedule A. Time course of MPA concentrations. (a)
Group 1; (b) Group 2 (see text for definition of groups).
interpatient variability is marked (Blossey et al., 1984; Lober
et al., 1981), and times of up to 8 weeks have been reported
before steady state serum levels have been achieved (Schulz
et al., 1984).
Following a single oral dose, the time to reach peak serum
level increases proportionally dependent upon the dose given
from 2h after doses of 100 to 400mg to 7h after 1,200mg
(Salimtschik et al., 1980). The absolute value of the peak
serum level achieved is also dose dependent with a linear
increase proportional to dose up to 1,200mg (Pannutiet al.
1982). There follows a biexponential decay with a first phase
to half an approximately 4.4h and a second phase to half of
approximately 59h (Tammassia et al., 1983). A loading dose
regimen employing MPA 1 g 6 hourly was therefore chosen
as this could be fully absorbed and it was predicted that a
high initial serum level would be achieved and thereafter
maintained. It was unclear from previously reported studies
how long the loading would need to be continued to avoid a
transient fall in serum level once the normal maintenance
regimen was started.
The optimum oral dose of MPA is as yet unclear.
Renewed interest in MPA for the treatment of advanced
breast cancer was stimulated by reports of very encouraging
response rates when using high doses of the drug (Pannuti et
al., 1978), and subsequently a dose response curve was
suggested (Cavelli et al., 1984; Tammassia et al., 1983).
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Figure 3 Schedule B. Time course of MPA concentrations. (a)
Group 1; (b) Group 2 (see text for definition of groups).
Retrospective correlations of serum level versus response
have been used to support the concept of 'high-dose' MPA,
with patients achieving serum levels in excess of 80-
lOOngml-l having more chance of responding than those
failing to reach these levels (Johnson et al., 1984; Schulz et
al., 1984; Tammassia et al., 1983). The dose required to
achieve these serum levels was 500mg i.m. twice weekly, and
increasing the dose beyond this resulted in increased toxicity
without further improving response rates (Robustelli Della
Cuna et al., 1978). Pharmacological studies suggested that
the oral dose which would result in equivalent serum levels
was I g daily (Tammassia et al., 1983), and this provided the
rationale for oral high-dose regimens. Recently two ran-
domised trials have suggesed that lower doses of MPA,
300mg daily, may be just as effective as the high-dose
regimens employing doses in the region of 1 g daily (Smith et
al., 1987; Rose et al., 1987), but neither trial was sufficiently
large to exclude a significant difference of up to 20%
between the two dosage schedules, and a subsequent trial
employing MPA at a dose of 300mg daily found no
responders out of 33 patients (Rose et al., 1987). Thus,
although the optimum dose and serum level of MPA remain
to be established, the variability of pharmacokinetic para-
meters between patients suggest that some pharmacological
failures will occur with lower dose regimens and conversely
1 g daily will be overdosing a proportion of patients. Those
patients in whom the drug accumulates slowly would still
have a chance of eventually responding provided that they
finally achieve an 'adequate' serum level, irrespective of the
absolute value of that level. In some cases, however, due to
the severity of the patient's symptoms and slow accumu-
lation of the drug, this may take too long to be acceptable
clinically. Thus, the time between initiating therapy and
achieving a response could influence the observed response
rate for hormonal therapy.
This study has shown that a loading dose regimen can
circumvent some of the pharmacological problems without
increasing toxicity. Despite marked inter-patient variability,
the 48h loading dose schedule better achieved the stated
objective of attaining plateau serum levels in the shortest
possible time. In most patients this also avoided the dip,
following the loading dose phase of the treatment, seen with
the shorter 24h loading dose schedule. Slow and fast
metabolisers of MPA have previously-been described (Blos-
sey et al., 1984), although they may represent the far ends of
a spectrum rather than two distinct groups of patients.
However, despite low initial serum levels of the drug in 3
patients treated using schedule B, all of these patients
eventually achieved high serum concentrations of MPA
during the loading dose phase of the study. It is not possible
to determine whether the marked variations in serum MPA
levels were due to individual differences in absorption or
metabolism of the drug.
The correct maintenance dose still awaits clarification by
prospective trial. If the maintenance dose in schedule B had
been 1,000mg daily then the absolute serum levels may have
continued to rise after the end of the loading dose phase of
the treatment resulting in higher plateau levels which took a
longer time to achieve. However, all 9 patients reached levels
in excess of 100ngml- by the end of the loading dose
phase and there is no evidence that looking for increases in
serum MPA concentration beyond this would be worthwhile.
The higher maintenance dose may also have prevented the
transient dip in MPA levels seen in 2 patients (Figure 3a)
and the later fall in serum MPA level seen in one patient by
8 weeks of treatment. Therefore, although a maintenance
dose of 500mg daily will be sufficient to maintain adequate
serum concentrations in a proportion of patients, once
plateau levels have been achieved, inter-patient differences in
handling the drug may result in some patients being under-
dosed, particularly if this regimen is initiated de novo.
We wish to acknowledge the help of Mr S. Virdee who performed
the assays. This study was supported by Farmitalia Carlo-Erba
(UK) Ltd.
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